Type I interferon subtypes differentially activate the anti-leukaemic function of natural killer cells

Natural killer (NK) cells have an intrinsic ability to detect and eliminate leukaemic cells. Cellular therapies using cytokine-activated NK cells have emerged as promising treatments for patients with advanced leukaemia. However, not all patients respond to current NK cell therapies, and thus improvements in efficacy are required.

Citation:
Barnes SA, Audsley KM, Newnes HV, Fernandez S, de Jong E, Waithman J, Foley B. Type I interferon subtypes differentially activate the anti-leukaemic function of natural killer cells. Front Immunol. 2022;13

Keywords:
Adoptive cell therapy; immunotherapy; interferon subtypes; leukemia;
natural killer cells

Abstract:
Natural killer (NK) cells have an intrinsic ability to detect and eliminate leukaemic cells. Cellular therapies using cytokine-activated NK cells have emerged as promising treatments for patients with advanced leukaemia. However, not all patients respond to current NK cell therapies, and thus improvements in efficacy are required.